FDA accepts for priority review BLA for epcoritamab for the treatment of relapsed/refractory large B-cell lymphoma
Genmab A/S announced that the FDA has accepted for Priority Review the Biologics License Application (BLA) for subcutaneous epcoritamab (DuoBody-CD3xCD20), an investigational bispecific antibody, for the treatment of patients with relapsed/refractory large B-cell lymphoma (LBCL) after two or more lines of systemic therapy
Under the Prescription Drug User Fee Act (PDUFA), the FDA has set a target action date of 21 May, 2023.
The BLA submission is based on safety and preliminary efficacy data from the LBCL cohort of the pivotal EPCORE NHL-1 open-label, multi-center phase II clinical trial evaluating epcoritamab in patients with relapsed, progressive or refractory CD20+ mature B-cell non-Hodgkin lymphoma (B-NHL). These results were presented in a late-breaking oral presentation as a part of the Presidential Symposium at the 27th Annual Meeting of the European Hematology Association (EHA2022), in Vienna, Austria.
In October 2022, the European Medicines Agency validated for review a Marketing Authorization Application (MAA) for epcoritamab for the treatment of patients with relapsed/refractory DLBCL– a major subtype of LBCL – after two or more lines of systemic therapy.
Related news and insights
Cidara Therapeutics announced the peer-reviewed publication of data from the completed pivotal ReSTORE Phase III clinical trial evaluating the efficacy and safety of its once-weekly antifungal candidate rezafungin as a potential treatment for candidemia and invasive candidiasis
Zynerba Pharmaceuticals announced that the results from the Phase III CONNECT-FX study of Zygel (cannabidiol gel synthetic) for the treatment of behavioral symptoms in children and adolescents with Fragile X syndrome (FXS) were published in the Journal of Neurodevelopmental Disorders
Eli Lilly and Company has announced the launch of the additional indication for Ramiven (abemaciclib), following approval from the Drugs Controller General of India (DCGI) in combination with endocrine therapy for adjuvant treatment in adult patients with Hormone Receptor (HR)-positive, human epidermal growth factor receptor 2(HER2) negative, node-positive Early Breast Cancer (EBC) at high risk of recurrence